NOVO NORDISK A/S
Commented by Fabian Lorenz on December 3rd, 2025 | 10:20 CET
US government strengthens Bayer! Almonty next? What is Novo Nordisk doing?
A bombshell at Bayer: The US government has officially sided with the Company. If the Supreme Court follows the recommendation, the Leverkusen-based company could largely put the glyphosate issue behind it as early as next year. Investors and analysts are enthusiastic. Almonty Industries is also in intensive discussions with the US government. CEO Lewis Black emphasized this in an interview with Fox Business. The Company plans to start mining tungsten, which is critical for defense and aerospace, among other things, in the US as early as next year. Since 2015, the US has been 100% dependent on imports. Analysts see 40% upside potential. Novo Nordisk shares are currently looking for a bottom. To reduce its dependence on Ozempic, the Danes have concluded a billion-dollar deal.
Read
Commented by Armin Schulz on December 2nd, 2025 | 07:00 CET
The demographic clock is ticking: How Bayer, Vidac Pharma, and Novo Nordisk are positioning themselves in the billion-dollar battle for our health
The demographic clock is ticking inexorably. An aging society brings with it a flood of widespread diseases such as heart disease, cancer, and diabetes. Each one is a billion-dollar market that is pushing healthcare systems to their limits. As costs explode, brutal, cut-throat competition is emerging. The winner will not be the one with the most pills, but the one with the most effective solutions to the greatest medical and economic challenges of our time. Today, we take a look at how Bayer, Vidac Pharma, and Novo Nordisk plan to shape the future.
Read
Commented by André Will-Laudien on November 27th, 2025 | 07:55 CET
Black Friday: DAX explodes, and biotech is back in vogue: Watch out for 100% gains at Bayer, Vidac Pharma, and Novo Nordisk
The stock market has managed to break out of its consolidation phase, and the upward trend is continuing toward the end of the year. There are signs of hope for the Leverkusen-based pharmaceutical company Bayer, and Vidac Pharma is moving into the primary segment of the Düsseldorf over-the-counter market. The well-known Novo Nordisk, whose share price has been destroyed, is experiencing its fourth sell-off in three months. Some analysts are now turning positive. Investors should now be aware that prices in the biotech sector have fallen so low that even minor news items are enough to cause prices to skyrocket. Especially during the year-end portfolio adjustments, prices often reach absurd levels. We help you navigate the thicket of valuations.
Read
Commented by André Will-Laudien on November 18th, 2025 | 07:25 CET
Nvidia figures ahead, AI correction looming? Doubling alternatives include Planethic Group, Bayer, Eli Lilly, and Novo Nordisk
It does not always have to be Nvidia! If the current level of risk on the NASDAQ feels a bit too high, investors should take a look at some European gems. There may be less AI involved here, but people still work for people. This is particularly interesting as Elon Musk aims to equip the core zone of human interaction with humanoid robots, from cooking together in the kitchen to family life, which could receive "digital offspring" as early as 2027. Because the planet will soon face food and water shortages due to permanent overheating, we are taking a closer look at completely analog topics such as alternative nutrition and the prevention of obesity. This is certainly too boring for the disciples of the digital apocalypse, but it offers plenty of charm for non-digital investors.
Read
Commented by Armin Schulz on November 13th, 2025 | 07:25 CET
Underrated stocks? A look at the growth drivers of Novo Nordisk, Planethic Group, and Puma
When prices fall, strategic investors sense their biggest opportunity. In the calm before the next upswing, there are undervalued gems that are ready for their turnaround. These are established players who are not only consolidating their core businesses but are already pulling the levers for tomorrow's growth. They are transforming their business models, tapping into new markets and focusing on forward-looking technologies, often unnoticed by the broader market. This transformation is what makes companies such as pharmaceutical giant Novo Nordisk, sustainability pioneer Planethic, and sporting goods manufacturer Puma particularly interesting right now.
Read
Commented by Fabian Lorenz on November 7th, 2025 | 07:00 CET
Takeover battle between Novo Nordisk and Pfizer! Is BioNxt Solutions the next target?
Who will acquire Metsera? That is currently the subject of dispute between Novo Nordisk and Pfizer. Both pharma giants are seeking access to a new generation of metabolic therapies through the acquisition - treatments that have the potential to transform the billion-dollar market for obesity and diabetes care. Novo Nordisk views Metsera's drug pipeline as a complement to its GLP-1-based preparations, while Pfizer is trying to finally gain a foothold in the market after several setbacks. The takeover battle illustrates that big pharma companies are willing to dig deep into their pockets for innovations. This makes BioNxt Solutions a potential takeover candidate. The Company is not only working on innovations in the field of multiple sclerosis and obesity, but on an entire platform technology.
Read
Commented by André Will-Laudien on November 6th, 2025 | 07:10 CET
Novo Nordisk calculating carefully, Evotec facing potential takeover? Clinical trial and up-listing at Vidac!
The stock market is showing some turbulence in the biotech sector. Unlike the big growth stocks on the NASDAQ, there is still urgent catching-up to do here. Some figures, such as those from Novo Nordisk and Evotec, still give reason for concern. The situation is quite different at Vidac Pharma, where an up-listing to the primary market is on the horizon and a clinical trial is about to begin! Plenty of material for investors' dreams to grow. We calculate where an investment is worthwhile!
Read
Commented by André Will-Laudien on November 4th, 2025 | 07:30 CET
Amazing! Rollercoaster ride with Beyond Meat, recovery at Novo Nordisk and Eli Lilly, big returns with PanGenomic Health
Volatility in the growth stock sector has caused quite a few swings in recent weeks. While Novo Nordisk and Eli Lilly are still struggling with margin declines from semaglutide injections, shares of the plant-based meat provider Beyond Meat have been bouncing around like a ball in orbit. After a rapid tenfold increase in October, November appears to be all about the reverse gear, with the stock currently down 80% from its peak. Those with strong nerves and a quick hand on the mouse are in luck. Things are calmer and steadier with PanGenomic Health. Here, the high levels since summer must first be digested before the next upward cycle can begin. We highlight a few opportunities.
Read
Commented by Armin Schulz on October 30th, 2025 | 07:25 CET
A new era in medicine is dawning: How Novo Nordisk, NetraMark Holdings, and Bayer are benefiting from AI and personalization
The healthcare industry is on the cusp of a new era, driven by AI-powered personalized therapies that are not only prolonging lives but also reshaping markets worth billions. Those who identify the pioneers of this transformation early on could benefit from extraordinary growth opportunities. Three companies, Novo Nordisk, NetraMark Holdings, and Bayer, are positioning themselves at the heart of this profitable field with groundbreaking technologies and therapies.
Read
Commented by Carsten Mainitz on October 23rd, 2025 | 07:25 CEST
AI hidden gem NetraMark Holdings is poised for a price surge, TeamViewer crash, and Novo Nordisk supervisory board resigns! What to do?
Artificial intelligence (AI) is widely regarded as a key technology with enormous potential across all industries. The use of AI opens up new opportunities, particularly in the biotechnology and pharmaceutical industries: from faster identification of potential active ingredients to more precise diagnostics and the automation of complex laboratory processes. Companies that make targeted use of AI gain competitive advantages in a highly competitive environment. Following a broad-based bull market, it is worth exploring promising second-tier players.
Read